Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vanda Pharmaceuticals Inc.

NASDAQ: VNDA · Life Sciences · 3 alerts · CIK 1347178

Share price
$3.81Close, Nov 16
Market cap
$230M
Shares outstanding
60.47MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vanda Pharmaceuticals Inc. filings on SEC EDGAR ↗

8:01 AM ET 10-Q
Financial Results

Vanda Pharmaceuticals Q3 2026 Results: Net Loss of $22.6M, Loss Narrows

Vanda Pharmaceuticals reported a significant decrease in total assets from $488.9 million at year-end 2025 to $382.3 million as of September 30, 2026, primarily driven by a reduction in marketable securities. The company's accumulated deficit increased to $528.4 million, reflecting ongoing losses, while total stockholders' equity declined to $199.9 million.

Key figure
Net loss $22.6M
4:07 PM ET 8-K
Financial Results

Vanda Pharmaceuticals Financial Results

Vanda Pharmaceuticals reported Q3 2026 total revenues of $69.8 million, a 24% year-over-year increase driven by Fanapt momentum and the commercial launch of NEREUS. Operating expenses decreased 18% sequentially to $93.3 million as major Phase III and launch-preparation activities began to conclude. The company is preparing for the Q4 2026 launch of BYSANTI and awaits an FDA decision on the Quimilza BLA in December.

Term
Q3 2026

“We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude.”

Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board

“Looking ahead, with the commercial launch of BYSANTI expected in the fourth quarter, the Quimilza BLA under FDA review with a December PDUFA date, and positive Phase III results supporting potential expansions for NEREUS in GLP-1-induced vomiting and HETLIOZ in Delayed Sleep-Wake Phase Disorder, we are focused on further moderating costs and driving revenue growth from our current portfolio and planned launches to support sustainable long-term value.”

Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.